Educational reference only. Not medical advice. Consult a healthcare provider before starting any protocol.
DSIP
Delta Sleep-Inducing Peptide (Emideltide)
What it is
A nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from the cerebral venous blood of rabbits during electrically induced sleep by Schoenenberger and Monnier at the University of Basel (characterized in PNAS, 1977). Despite nearly five decades of research, no specific receptor, gene, or precursor protein has been identified for DSIP. Multiple mechanisms have been proposed including GABAergic modulation, HPA axis suppression, alpha-1-adrenergic modulation of pineal melatonin synthesis, opioid receptor interaction, and enhanced mitochondrial oxidative phosphorylation. DSIP freely crosses the blood-brain barrier and is unusually absorbed intact from the gut. Only the alpha-aspartyl form at position 5 is biologically active. Limited human pilot studies exist for pain and withdrawal, but no completed randomized clinical trials have been published.
Community-reported ranges
Ranges sourced from community forums, limited clinical pilot studies, and published preclinical/review literature. Not dosing guidance.
Reported dose range
100–300 mcg
Estimated half-life
~7-8 minutes (free peptide in plasma)
Source: human pharmacokinetic data (Eur J Anaesthesiol 2001 review); endogenous carrier-bound form has longer effective duration
Reported cycle length
2–4 weeks on
2-4 weeks off
Route
subcutaneous
Common vial sizes
2mg, 5mg
Reported timing
30-60 min before bed
Reported frequency
1x daily (30-60 min before bed)
Frequently discussed alongside
Based on community forum discussions. Not a recommendation to combine compounds.
Selank
Both are neuroactive peptides targeting CNS pathways; both were placed on the FDA Category 2 list; frequently combined in community sleep/anxiolytic protocols
Semax
Both are neuroactive peptides on the FDA Category 2 list; discussed together in nootropic and neuromodulation contexts
Epithalon
Overlapping circadian and pineal regulation — DSIP modulates pineal N-acetyltransferase (melatonin synthesis) while Epithalon activates telomerase in pinealocytes
Published research
DSIP was characterized via cross-circulation experiments between sleeping and awake rabbits (Schoenenberger & Monnier, PNAS 1977), showing a 35% increase in delta EEG activity. Despite decades of study, the Kovalzon & Strekalova 2006 review (J Neurochem) concluded the sleep-factor hypothesis remains poorly documented and no receptor or gene has been identified. Research has extended to opioid and alcohol withdrawal, pain modulation via supraspinal opioid pathways, stroke recovery (intranasal in rat MCAO models), depression (altered plasma/CSF levels), and cancer biology (2.6-fold decrease in spontaneous tumor incidence in mice, 24.1% increase in maximum lifespan). Small human pilot studies exist for chronic pain and insomnia, but no peer-reviewed randomized controlled trials have been completed as of March 2026. Community dosing protocols are based on limited clinical pilot data and anecdotal experience.
Reported side effects
From community self-reports. Not from controlled studies.
Community users have reported headaches (commonly cited as an indicator of excessive dosing), morning grogginess, daytime drowsiness, vivid dreams, and occasional paradoxical insomnia (particularly at initiation or higher doses, often resolving with dose reduction). Mild dizziness and gastrointestinal discomfort are occasionally noted. Some users report that extended daily use can cause rebound insomnia upon discontinuation. A study of 107 human volunteers found the peptide generally well-tolerated. Systematic long-term safety data in humans does not exist.
Regulatory status
FDA (United States)
Not approved. Listed as Category 2 (under the name Emideltide) on the FDA 503A bulk drug substances interim policy, citing immunogenicity concerns — effectively prohibiting pharmacy compounding. As of March 2026, potential reclassification has been announced but not officially published.
Health Canada
Not authorized as a therapeutic product. No DIN assigned. Health Canada has issued warnings about unauthorized injectable peptide sales.
WADA (Competitive Athletes)
Not specifically named on the 2025/2026 Prohibited List. Could fall under S0 (Non-approved substances) on a case-by-case basis for competitive athletes.
Requires free account · 7-day trial included